How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation

Therapeutic Drug Monitoring

Volumn 33, Issue 2, 2011, Pages 155-164

  Van Gelder, Teun ^a   Silva, Helio Tedesco ^b   De Fijter, Hans ^c   Budde, Klemens ^d   Kuypers, Dirk ^e   Mamelok, Richard D ^f   Armstrong, Victor W ^g   Oellerich, Michael ^g  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f Mamelok Consulting   (United States)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

mycophenolate mofetil; therapeutic drug monitoring; transplantation

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AREA UNDER CURVE; CREATININE; CYCLOSPORINE; DELAYED GRAFT FUNCTION; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; OPPORTUNISTIC INFECTIONS; TACROLIMUS; TREATMENT FAILURE;

EID: 79953204258     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31820c0a96     Document Type: Article

References (35)

1. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6: 1111-1131.
2. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3:534-542. (Pubitemid 36612836)
3. Bennett WM. Immunosuppression with mycophenolic acid: one size does not fit all. J Am Soc Nephrol. 2003;14:2414-2416. (Pubitemid 37052391)
4. Van Gelder T. Mycophenolate mofetil: how to further improve using an already successful drug? Am J Transplant. 2005;5:199-200. (Pubitemid 40179503)
5. Van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17:871-880.
6. Van Hest RM, van Gelder T, Bouw R, et al. Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol. 2007;63:741-752. (Pubitemid 46753575)
7. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455. (Pubitemid 28273453)
8. Van Hest RM, van Gelder T, Vulto AG, et al. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2005;44:1083-1096. (Pubitemid 41356393)
9. Atcheson BA, Taylor PJ, Mudge DW, et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol. 2005;59:271-280. (Pubitemid 40388081)
10. Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2000;40:624-633.
11. Kuypers DR, Chapman JR, O'Connell PJ, et al. Predictors of renal transplant histology at three months. Transplantation. 1999;67: 1222-1230. (Pubitemid 29239472)
12. van Gelder T, Tedesco Silva H, de Fijter JW, et al. comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the Fixed-Dose Concentration-Controlled (FDCC) Trial. Transplantation. 2008;86:1043-1051.
13. Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002; 48:1497-1504. (Pubitemid 34925784)
14. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monitor. 2000;22:167-173.
15. Weber LT, Hoecker B, Armstrong VW, et al. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monitor. 2006;28: 623-631. (Pubitemid 44564060)
16. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713-723. (Pubitemid 29082898)
17. Shipkova M, Niedmann PD, Armstrong VW, et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem. 1998;44:1481-1488. (Pubitemid 28309109)
18. Streit F, Shipkova M, Armstrong VW, et al. Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. Clin Chem. 2004;50:152-159. (Pubitemid 38125712)
19. Quiroga I, McShane P, Koo DD, et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant. 2006;21:1689-1696. (Pubitemid 44063135)
20. Woodle ES, Alloway RR, Buell JF, et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant. 2005;5:2740-2744.
21. Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant. 2004;4:1079-1083. (Pubitemid 38868597)
22. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683. (Pubitemid 29011387)
23. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41:1011-1017.
24. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13: 759-768. (Pubitemid 34183943)
25. Van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005;80(Suppl): S244-S253. (Pubitemid 41552911)
26. Kaplan B, Meier-Kriesche HU, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol. 1999;39:715-720.
27. Kaplan B, Gruber SA, Nallamathou R, et al. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation. 1998;65:1127-1129. (Pubitemid 28208433)
28. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol. 1998;9:1511-1520. (Pubitemid 28354563)
29. Shaw LM, Mick R, Nowak I, et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998;38:268-275. (Pubitemid 28144932)
30. Atcheson BA, Taylor PJ, Mudge DW, et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol. 2005;59:271-280. (Pubitemid 40388081)
31. Zanker B, Schleibner S, Schneeberger H, et al. Mycophenolate mofetil in patients with acute renal failure: evidence of metabolite (MPAG) accumulation and removal by dialysis. Transpl Int. 1996;9(Suppl 1):S308-S310.
32. Johnson HJ, Swan SK, Heim-Duthoy KL, et al. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther. 1998;63:512-518. (Pubitemid 28277272)
33. Beal JL, Jones CE, Taylor PJ, et al. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. Ther Drug Monit. 1998;20:685-690. (Pubitemid 28544302)
34. Shipkova M, Schutz E, Armstrong VW, et al. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplant Proc. 1999;31:1135-1137. (Pubitemid 29127843)
35. Weber LT, Shipkova M, Armstrong VW, et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem. 2002;48:517-525. (Pubitemid 34174582)